Latest news with #TrungHuynh
Yahoo
5 days ago
- Business
- Yahoo
UBS Raises Regeneron (REGN) Price Target, Maintains Neutral Rating
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is one of the Best Non-Mega Cap NASDAQ Stocks to Buy Right Now. UBS analyst Trung Huynh raised the price target on Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) to $584 from $560 while maintaining a rating ahead of the company's second-quarter earnings report. A pharmacist in a lab coat carefully analyzing a vial of medicine for its quality. The move reflects slightly more optimistic expectations for Regeneron's financial performance, particularly driven by the continued strength of its flagship eye treatment, Eylea. The franchise has shown resilience amid increased competition in the ophthalmology space, and investor attention is likely to focus on how well Regeneron has defended its market share. Despite the upward revision, UBS remains cautious on the stock, pointing to a balance of risks and rewards in the near term. While the company has a robust pipeline and strong positioning in its core therapeutic areas, the firm believes the current share price already reflects much of the near-term optimism. The note also signals that while the broader biotech sector has experienced renewed investor interest, Regeneron's valuation leaves limited room for upside unless new catalysts emerge. The stock has performed steadily in recent months, and the upcoming earnings release may serve as a key moment for reassessing momentum into the second half of the year. While we acknowledge the potential of REGN as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: Top 10 Healthcare AI Stocks to Buy According to Hedge Funds and 10 Consumer Defensive Stocks to Buy Now. Disclosure: None. This article is originally published at Insider Monkey.
Yahoo
09-07-2025
- Business
- Yahoo
UBS Affirms Merck & Co's (MRK) ‘Buy' Rating on HPV Vaccine Prospects
Merck & Co., Inc. (NYSE:MRK) is one of the 10 best defensive stocks to buy in a volatile market. On July 2, UBS reiterated a 'Buy' rating on the stock and a $105 price target. According to analyst Trung Huynh, the company's human papillomavirus (HPV) vaccine, Gardasil, is a key driver of growth. 360b / Huynh insists investors have only shown limited near-term interest in the stock ahead of key inflection points. For starters, the return of Gardasil shipments to China is expected to bolster the company's revenue base. According to the investment firm Gardasil, inventory levels in China remain elevated owing to expanded promotional efforts spanning five regions. Following $200 million in shipments into China, UBS does not expect additional shipments. However, it expects Merck to generate up to $5.8 billion in Gardasil sales. Additionally, Huynh is optimistic about the full Phase 3 oral PCSK9 CORALreef Lipids readout in hypercholesterolemia. Merck & Co., Inc. (NYSE:MRK) develops and provides solutions in areas like biopharmaceutical therapies, scientific research tools, and materials for electronics, including smartphones and televisions. While we acknowledge the potential of MRK as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: and . Disclosure: None. This article is originally published at Insider Monkey. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Business Insider
13-06-2025
- Business
- Business Insider
Analysts Conflicted on These Healthcare Names: Pfizer (PFE) and Chemomab Therapeutics (CMMB)
Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Pfizer (PFE – Research Report) and Chemomab Therapeutics (CMMB – Research Report). Confident Investing Starts Here: Pfizer (PFE) In a report released today, Trung Huynh from UBS maintained a Hold rating on Pfizer, with a price target of $25.00. The company's shares closed last Thursday at $24.84, close to its 52-week low of $24.48. According to Huynh is a 5-star analyst with an average return of 13.3% and a 68.9% success rate. Huynh covers the Healthcare sector, focusing on stocks such as Acumen Pharmaceuticals, ALX Oncology Holdings, and Bristol-Myers Squibb. Currently, the analyst consensus on Pfizer is a Moderate Buy with an average price target of $27.69, which is a 12.9% upside from current levels. In a report issued on June 4, Bernstein also maintained a Hold rating on the stock with a $30.00 price target. In a report released yesterday, Michael Okunewitch from Maxim Group maintained a Buy rating on Chemomab Therapeutics, with a price target of $7.00. The company's shares closed last Thursday at $1.22. According to Okunewitch is ranked 0 out of 5 stars with an average return of -17.0% and a 34.3% success rate. Okunewitch covers the Healthcare sector, focusing on stocks such as Radiopharm Theranostics Limited Sponsored ADR, Acrivon Therapeutics, Inc., and Rani Therapeutics Holdings. Currently, the analyst consensus on Chemomab Therapeutics is a Moderate Buy with an average price target of $8.50.
Wall Street Journal
03-04-2025
- Business
- Wall Street Journal
Pharma Stocks Aren't in the Clear, Despite Tariff Exemption—Heard on the Street
Big pharmaceutical stocks mostly rose after President Trump's executive order exempted medicines from new tariffs. Merck, Bristol-Myers Squibb, and Johnson & Johnson were among the top performers in the S&P 500, with the sector also benefiting from its status as a defensive play. Still, drugmakers aren't in the clear. Trump singled them out in his remarks Wednesday, saying: 'The pharmaceutical companies are going to come roaring back… because if they don't, they got a big tax to pay.' That underscores Trump's 'continued appetite to effect change in the industry,' said UBS analyst Trung Huynh. One possible scenario is Trump introduces tariffs specifically targeting pharma—either all at once, or in stages—said Huynh. The president could also pursue tax reform aimed at the industry's offshore tax shelters. For now, pharma is breathing a sigh of relief. But the reprieve may be temporary.
